Низкомолекулярные гепарины в практике нефролога


Н.Л. Козловская

ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ, Москва
Обсуждаются основные аспекты применения низкомолекулярных гепаринов у нефрологических больных. Рассмотрены подходы к профилактике и лечению тромбозов при нефротическом синдроме и нарушении функции почек.

Литература


1. Кутырина И.М., Никишова Т.А., Лифшиц Н.Л. и др. К механизму диуретического эффекта гепарина при хроническом гломерулонефрите. Тер. архив. 1982;7:42–46.
2. Кутырина И.М., Никишова Т.А., Тареева И.Е. Гипотензивное и диуретическое действия гепарина у больных хроническим гломерулонефритом. Тер. архив. 1985;6:78–81.
3. Mandal A.K., Lyden T.W., Saklaen M.G. Heparin lowers blood pressure. Kidney Int. 1995;47:1017–1022.
4. Gambaro G., Baggio B. Glycosoaminoglicans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol. Dial. Transplant. 1996;11:762–764.
5. Gambaro G., Morita Y., Makino H. et. al. Effect of heparin and lowmolecular – weight- heparin on proliferative glomerulonephritis. Nippon-Jinzo-Gakkai-Shi. 1994;36:823–838.
6. Striker G.E., Lupia E., Eliot S. et al. Glomerulosclerosis, arteriosclerosis and vascular graft stenosis: Treatment with oral heparinoids. Kidney Int. 1997;52:S120–S123.
7. Abilgaard U., Lindahl A.L., Sandset P.M. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 1991;21:254–257.
8. Hoppensteadt D.A., Walenga J.M., Fasanella A. et al. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight
heparin. Thromb Res 1995;77:175–181.
9. Sandset P.M., Bends B., Hancen J.B. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000;30(Suppl. 2):48–56.
10. Vila V., Martinez-Sales V., Reganon E. et al Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes. Haematologica 2001; 86:729–734.
11. Yamamoto N., Ogawa H., Oshima S. et al. The effect of heparin on tissue factor and tissue factor pathway inhibitor in patients with acute myocardial infarction. Int J. Cardiol. 2000;75:267–274.
12. Cadroy Y, Gaspin D, Duppuy D, et al Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb. Haemost. 1996; 75:190–195.
13. Pepe G, Guisti B, Attanasio M et al. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin. Thromb. Hemost. 1997;23:135–141.
14. Weithz J.L. Low molecular weight heparins. N. Engl. J. Med. 1997;337:688–699.
15. Cardoy Y., Pourrat J., Balagre M.F. et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb. Res. 1991;63:385–390.
16. Orth S.R., Ritz E. The nephrotic syndrome. N. Eng. Jorn. Med. 1998;338:1202–1211.
17. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985;28:429–436.
18. Crew R.J., Radhakrishnan S., Appel G. Complications of nephrotic syndrome and their treatment. Clin Nephrol. 2004;62:245–251.
19. Donckerwolcke R.A., Cameron J.S. The nephrotic syndrome: management, complications and pathophysiology. In Davison A.M., Cameron J.S., Grunfeld J.P., Ponticelli C., Ritz E., Winearls C., Ypersele C. (Ed.) Oxford Textbook of Clinical Nephrology, Third Edition. Oxford University Press,
2005:415–436.
20. Rabelink T.J., Zwaginga J.J., Koomans H.F. et al. Thrombosis and hemostasis in renal disease. Kidney Int 1994;46:287–296.
21. Robert A., Olmer M., Sampol J. et al. Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int 1994;45:578–85.
22. Mahmoodi B.K., Ten Kate M.K., Waanders F. et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome. Results from a large retrospective cohort srudy. Circulation 2008;117:224–230.
23. Bertina R.M. Genetic approach to thrombophilia. Thromb. Haemost. 2001;86:92–99.
24. Баранникова Е.И., Козловская Н.Л., Понкина О.Н. и др. Генетическая гипергомоцистеинемия как причина артериальных и венозных тромбозов у больного хроническим гломерулонефритом. Нефрология и диализ 2008;10(3–4):254–258.
25. Bellomo R., Atkins R.C. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993;63:249–254.
26. Clagett G., Anderson F., Geerts W.H. et al. Prevention of venous thromboembolism. Chest. 1998;114(Suppl.):531S–560S. 27. Attia J., Ray J., Cook D.J. et al. Deep venous thrombosis and its prevention in critically ill adults. Arch. Intern. Med. 2001;161(10):1268–1279.
28. Cook D.J., Crowter M., Meade M. et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence and risk factors. Crit. Care Med 2005;33(7):1268–1279.
29. Geerts W.H., Pineo G.F., Heit A.J. et al. Prevention of venous thromboembolism: the seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 Suppl.):338S–400S.
30. Samama M., Cohen A., Darmon J.Y. et al. Сравнение эффективности эноксапарина и плацебо в профилактике тромбозов и эмболий у пациентов с острыми терапевтическими заболеваниями. Клин.
фарм. Терапия. 2001;10:90–95.
31. Leizorovicz A., Cohen A.T., Turpie A.G. et al. Randomized, placebocontrolled trial of dalteparin for prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874–879.
32. Monreal M., Falga C., Valle R, et al. Venous thromboembolism in patients with renal insufficiency: finding from the RIETE Registry. Am. J. Med. 2006;119:1073–1079.
33. Wattanakit K., Cushman M., Stehman-Breen C., et al. Chronic kidney disease increased risk for venous thromboembolism. J. Am. Soc. Nephrol. 2008;19:135–140.
34. Tveit D.P., Hypolite I.O., Hshieh P. et al. Chronic dialysis patients have high risk for pulmonary embolism. Am. J. Kidney Dis. 2002; 39:1011–1017.
35. Daneschvar H.L., Seddighzadeh A., Piazza G. et al. Deep vein thrombosis in patients with chronic kidney disease. Thromb. Haemost. 2008;99:1035–1039.
36. D©Elia J.A., Weinrauch L.A., Gleason R.E. et al. Risk factors for thromboembolic events in renal failure. Int. J. Cardiol. 2005;101:19–25.
37. Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int. 2002;62:1408–1416.
38. Ando M, Iwata A, Ozeki Y et al. Circulated platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002;62:1757–1763.
39. Reich LM, Folsom AR, Key NS, et al. Prospective study of subclinical atherosclerosis as a risk for venous thromboembolism. J. Thromb. Haemost. 2006;4:1909–1913.
40. Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006;355:2085–2098.
41. Lim W., Dentali F., Eikelboom J.W. et al. Meta-analysis: low-molecularweight heparin and bleeding in patients with severe renal insufficiency. Ann. Intern. Med. 2006;144:673–684.
42. Falga C., Capdevila J.A., Soler S. et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb. Haemost. 2007;98(4):771–776.
43. Santopino J.J., Fox K.A., Goldberg R.J. et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: finding from the global registry of acute coronary events (GRACE). Heart. 2003;89(9):1003–1008.
44. Thorevska N., Amoateng-Adjepong Y., Sabahi R. et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest. 2004;125:856–863. 45. Antman E.M., McCabe C.H., Gurfinkel E.P. et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIB trial. Circulation 1999;100:1593–1600.
46. Collet J.P., Montalescot G., Agnelli G. et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of lowmolecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur. Heart. J. 2005;26:2285–2293.
47. Collet J.P., Montalescot G., Fine E. et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J. Am. Coll. Cardiol. 2003;41:8–14.
48. Schmid P., Fisher A.G., Wuillemin W.A. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med WKLY 2009; 139(31–32):438–452.
49. Collet J.P., Montalescot G., Choussat R. et al. Enoxaparin in unstable angina patients with renal failure. Int. J. Cardiol. 2001;80:81–82.
50. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Hemostasis 1996;26(Suppl. 2):24–38.
51. Samama M.M., Gerotziafas G.T. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000;26(Suppl. 1):31–38.
52. Schmid P., Fischer A.G., Wuillemin W.A. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med WKLY 2009; 139(31–32):438–452.
53. Tincani E., Mannucci C., Casolari B. et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 2006;91:976–979.
54. Stobe J., Siegemund A., Achenbach H. et al. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int. J. Clin. Pharmacol. Ther. 2006;44:455–465.
55. Cook D., Douketis J., Meade M. et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Crit. Care. 2008;12:R32.
56. Douketis J., CooK D., Meade M. et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of
safety and pharmacodynamics: the DIRECT study. Arch. Intern. Med. 2008;168(16):1805–1812.
57. Schmid P., Brodmann D., Fischer A.G. et al. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J. Thromb. Haemost. 2009;7:552–558.
58. Rabbat C.G., Cook D., Crowter M.A. et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J. Crit. Care. 2005;20:357–363.
59. Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of venous thromboembolism: American college of chest physicians evidencebased clinical practice guidelines (8th edition.) Chest. 2008;133: 381S–453S.
60. Schulman S., Beyth R.J., Kearon C. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:257S–298S.
61. Samama M.M., Cohen A.T., Darmon J.Y. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with
enoxaparin study group. N. Engl. J. Med. 1999;341:793–800.
62. Schmid P., Fisher A.G., Wuillemin W.A. Prevalence of impaired renal function in medical inpatients. Swiss Med. Wkly. 2007;137:514–516.
63. Cook L.M., Kahn S.R., Goodwin J. et al. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical ptactice. J Thromb Haemost. 2007;5(5):937–941.
64. Alexander K.P., Chen A.Y., Roe M.T. et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108–3116.
65. La Pointe N.M., Chen A.Y., Alexander K.P. et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. Arch. Intern. Med.
2007;167(14):1539–1544.
66. Hirsh J., Bauer K.A., Donati M.B. et al. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:141S–159S.
67. Fareed J., Leong W.L., Hoppensteadt D.A. et al. Generic low-molecularweight heparins: some practical considerations. Semin. Thromb. Hemost. 2004;30:703–713.


Об авторах / Для корреспонденции


Козловская Н.Л. – профессор кафедры нефрологии и гемодиализа ФППОВ ГОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздравсоцразвития РФ, д.м.н. E-mail: nkozlovskaya@yandex.ru


Похожие статьи


Бионика Медиа